10 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.

Merck Research Laboratories
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.

Diatide Research Laboaratories
Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.

University of Arizona
The elucidation of somatostatin receptor functions: a current view.

German Institute of Human Nutrition
Differential expression of multiple somatostatin receptors in the rat cerebellum during development.

Dynamique Des Systemes Neuroendocriniens
Identification and characterization of novel somatostatin antagonists.

Cyenamid Agricultural Research Center